Analyzing Mind Medicine (MindMed) (MNMD) and The Competition

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Mind Medicine (MindMed) to similar businesses based on the strength of its analyst recommendations, dividends, profitability, earnings, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Mind Medicine (MindMed) and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 3 0 3.00
Mind Medicine (MindMed) Competitors 274 678 675 28 2.28

Mind Medicine (MindMed) currently has a consensus price target of 7.67, indicating a potential upside of 733.33%. As a group, “Medicinals & botanicals” companies have a potential upside of 109.30%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher probable upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than its competitors.

Insider & Institutional Ownership

12.4% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 19.5% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 28.2% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Mind Medicine (MindMed) and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mind Medicine (MindMed) N/A -$93.04 million -4.00
Mind Medicine (MindMed) Competitors $238.89 million -$88.70 million -7.82

Mind Medicine (MindMed)’s competitors have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Mind Medicine (MindMed) and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) N/A -55.27% -51.10%
Mind Medicine (MindMed) Competitors -179.08% -256.98% -16.14%

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with's FREE daily email newsletter.